Results 1 to 10 of about 42,801 (170)
Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12. [PDF]
PLoS ONE, 2012 Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of these signaling ...
Alison M McCaig +3 more
doaj +17 more sources
Dasatinib reverses Cancer-associated Fibroblasts (CAFs) from primary Lung Carcinomas to a Phenotype comparable to that of normal Fibroblasts [PDF]
Molecular Cancer, 2010 Cancer associated fibroblasts (CAFs) play a critical role for growth, invasion, and metastasis of cancer. Therefore, targeting CAFs with small molecule inhibitors may be an attractive anti-tumor strategy. The current study aims to identify small molecule
van der Kuip Heiko +6 more
doaj +4 more sources
Dasatinib targets c-Src kinase in cardiotoxicity
Toxicology Reports, 2023 Dasatinib is a multitargeted kinase inhibitor used for treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. Unfortunately, treatment of cancer patients with some kinase inhibitors has been associated with cardiotoxicity.
Manar Elmadani +8 more
doaj +1 more source
Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia
Respiratory Medicine Case Reports, 2022 Dasatinib, an effective second-generation tyrosine kinase inhibitor, is used to treat breakpoint cluster region-Ableson-positive chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia.
Go Makimoto +3 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 Dasatinib treatment is approved as first-line therapy for chronic myeloid leukemia. However, pulmonary hypertension (PH) is a highly morbid and often fatal side-effect of dasatinib, characterized by progressive pulmonary vascular remodeling.
Rui Wang +14 more
doaj +1 more source
Haematologica, 2023 Dasatinib is a multi-kinase inhibitor with activity against the SRC kinase LCK, which plays a critical role in T-cell receptor signaling. Dasatinib, initially developed as an immunosuppressive agent, is by contrast, also noted to result in enhanced ...
Patrick Harrington +12 more
doaj +1 more source
Frontiers in Oncology, 2023 Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second-line treatment for those who are resistant or intolerant to therapy with imatinib.
Fang Cheng +10 more
doaj +1 more source
Haematologica, 2013 Dasatinib is effective in most chronic phase chronic myeloid leukemia patients both in first-line therapy and following imatinib failure. While imatinib uptake into CD34+ cells is low compared to mononuclear cells, few data evaluate how well dasatinib ...
Devendra K. Hiwase +5 more
doaj +1 more source
Therapeutic Advances in Respiratory Disease, 2022 Dasatinib, a tyrosine kinase inhibitor, is usually prescribed for chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia. However, some patients may develop an intolerance to this drug over the years.
Sang-A Kim +5 more
doaj +1 more source
A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer. [PDF]
, 2015 Serous Ovarian Cancers (SOC) are frequently resistant to programmed cell death. However, here we describe that these programmed death-resistant cells are nonetheless sensitive to agents that modulate autophagy.
Bartakova, Alena +10 more
core +5 more sources